Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony rozpoznaniem rak piersi bez przerzutów do odległych narządów
- •Typ HR+/HER2- (określony rodzaj raka)
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-3)
- •Pacjent zakwalifikowany do leczenia uzupełniającego lekami CDK4/6
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Niemożność połykania tabletek lub zaburzenia wchłaniania w przewodzie pokarmowym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- November 19, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China
Trial contact
Wenjin Yin, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.